Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial

NCT02051218 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT02051218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02051218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 16, 2014
Completion date
December 31, 2028
Enrollment
1,380 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, metastatic breast cancer, metastatic prostate cancer